RCT of a Polyherbal Dietary Supplement for Prediabetes

Prediabetic State Clinical Trial

Official title:

A Randomized, Placebo-controlled Clinical Trial of a Polyherbal Dietary Supplement (GlucoSupreme™ Herbal) on Markers of Glycemic Control Among Prediabetic Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03388762
• Other study ID #: 022-DFH, HP-00075768
• Status: Completed
• Phase: N/A
• Start date: December 5, 2017
• Est. completion date: January 1, 2020

Study information

• Verified date: June 2022
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the impact of a polyherbal dietary supplement (Designs for Health - GlucoSupreme™ Herbal) on markers of glycemic control and other structure/function outcomes among a sample of prediabetic adults.

A 12-week randomized, double-blinded, placebo-controlled clinical trial will be conducted to achieve the purpose of this study. The research team hypothesizes that GlucoSupreme™ Herbal will improve a variety of validated markers of glycemic control that are commonly used in clinical practice more effectively than placebo.

Description:

Prediabetes is a common state in which blood glucose levels are elevated, but are not elevated high enough to be considered Type 2 Diabetes (T2D). The worldwide prevalence of prediabetes is high and rapidly increasing. People with prediabetes are at increased risk for developing a variety of chronic diseases. Most notably, prediabetes nearly always precedes diagnosis of T2D, a poorly-controlled disease adversely affecting 14% of adults in the United States. T2D is responsible for increased risk of heart disease, stroke, blindness and other vision problems, kidney disease, amputations and death. Prediabetes often progresses to T2D relatively quickly, as pancreatic beta-cell dysfunction perpetuates. There are currently limited pharmacological options available for safely reducing the burden of prediabetes. Furthermore, these pharmacological options often carry potentially deleterious side effects. Low-risk alternatives are needed where lifestyle modifications, such as increased physical activity and weight loss, have failed.

Herbal dietary supplements have shown promise in safely managing impaired glycemic control in prediabetic adults in many clinical studies. A wide variety of herbs have been previously studied for these purposes, including cinnamon, fenugreek, banaba, curcumin, and a variety of combination products. Of these, most have demonstrated improved management of glycemic control, particularly with regard to reducing fasting blood glucose and postprandial glucose, HbA1c, fasting insulin levels, HOMA-Insulin Resistance, and increasing HOMA-β cell function among prediabetic adult populations. Many herbs have also demonstrated benefit in the management of glycemic control in clinical trials among T2D populations. These herbs include berberine, ginseng, gymnema, banaba, cinnamon, fenugreek, and kudzu, all of which are present in GlucoSupreme™ Herbal.

The research team hypothesizes that GlucoSupreme™ Herbal will demonstrate superior improvements in markers of glycemic control than placebo over twelve weeks of daily supplementation among a sample of healthy adults. The research team aims to conduct a randomized, placebo-controlled, double-blinded clinical trial to evaluate this hypothesis among a diverse sample of 40 prediabetic adults, and will implement a 1:1 study allocation ratio. This study will utilize an adaptive sample size re-estimation (SSR) approach where participant enrollment may be extended beyond the originally planned sample size if interim effect size is smaller than anticipated, but still promising, thereby preserving study power; this will be determined by examination of available unblinded endpoint data by an independent statistician after 30 subjects are enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: January 1, 2020
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Prediabetic blood measurement (HbA1C) of 5.7-6.4% and/or fasting blood glucose of 100-125 mg/dl and/or 2-hour Oral Glucose Tolerance Test blood glucose value of 140 mg/dl-199 mg/dl1 2) taken within the last 12 weeks

3. Agree to continue with current diet and refrain from taking any new nutritional or herbal supplements

4. Able to understand and write English

5. Voluntarily consent to the study and understand its nature and purpose including potential risks and side effects

Exclusion Criteria:

1. Current daily use of any oral hypoglycemic medication or insulin injection

2. Current daily use of any supplement containing the herbs in the study supplement

3. Known allergies to any substance in the study supplement

4. Current daily tobacco smoker

5. Currently pregnant or planning to become pregnant in the next 12 weeks

6. Any current or previous diagnosis of diabetes (Type 1 or Type 2)

7. Myocardial infarction, vascular surgery, or stroke in the past year

Related Conditions & MeSH terms

• Prediabetic State

Intervention

Dietary Supplement:
• GlucoSupreme™ Herbal
This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.

Other:
• Placebo
The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.

Locations

Country	Name	City	State
United States	University of Maryland Center for Diabetes and Endocrinology	Baltimore	Maryland
United States	University of Maryland Family Medicine Associates	Baltimore	Maryland
United States	University of Maryland School of Medicine, Department of Family and Community Medicine, East Hall	Baltimore	Maryland
United States	Alliance Integrative Medicine	Cincinnati	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	Alliance Institute for Integrative Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting Blood Glucose	Elevated fasting blood glucose is one of the markers of the prediabetic state. According to American Diabetes Association criteria, the prediabetic fasting blood glucose range is 100 to 125 mg/dL (5.6 to 6.9 mmol/L). After fasting for 8-12 hours, > 0.5mL of blood will be collected from each participant, followed by centrifuge separation of plasma from cells within 45 minutes of collection. After maintaining the plasma fasting blood glucose at room temperature, it will be analyzed using standard enzymatic methodology.	Baseline and study end (12 weeks from baseline)
Primary	Glycated hemoglobin/A1C (HbA1c)	Elevated HbA1c is another one of the markers of the prediabetic state and is defined as being within the range of 5.7-6.4%. A four mL sample of whole blood will be obtained from participants using techniques described above, and placed in an EDTA, lithium heparin, or sodium fluoride tube, followed by analysis using the Roche Tina Quant (Roche, Germany).	Baseline and study end (12 weeks from baseline)
Primary	Fasting insulin	In prediabetes, pancreatic beta cells can no longer produce enough insulin to overcome insulin resistance, which can cause blood glucose levels to rise above the normal range. Thus, fasting insulin is a glycemic parameter of interest and is also used to determine insulin resistance. While normal values for fasting insulin are <25 microU/L, fasting insulin can vary widely among prediabetic individuals. After fasting for 8-12 hours, 0.8mL blood serum will be obtained from each participant. This fasting insulin assay will be performed using a 2-site electrochemiluminescent immunoassay on the Roche automated platform (Roche, Germany.).	Baseline and study end (12 weeks from baseline)
Primary	Insulin Resistance (HOMA-IR)	Insulin resistance often sets the stage for progression to T2D by placing a high demand on insulin-producing beta cells during a prediabetic state. The advantage of using the validated HOMA-IR calculation is its relative simplicity and low-cost since it is derived from other primary outcomes of interest in this study. HOMA-IR is calculated as: [Fasting insulin (microU/L) x Fasting Blood Glucose (nmol/L)]/22.5.	Baseline and study end (12 weeks from baseline)
Primary	ß-cell function (HOMA-ß)	Pancreatic beta cells (ß-cells) produce insulin. Thus, their function is of interest in this prediabetic study population. As is the case with HOMA-IR, this formula utilizes values from our other study outcomes. HOMA- ß is calculated as: (20 x Fasting insulin [microU/L])/(Fasting blood glucose [mmol/l] - 3.5).	Baseline and study end (12 weeks from baseline)
Primary	Quantitative Insulin Sensitivity Check Index (QUICKI)	The validated QUICKI measurement to assess insulin sensitivity has also been studied in herbal dietary supplement clinical trials. QUICKI is calculated as: 1/(log-fasting blood glucose [mg/dL] + log-fasting insulin [uU/mL]).	Baseline and study end (12 weeks from baseline)
Primary	Fructosamine	Many serum proteins are involved in glucose synthesis. Fructosamine represents the degree of glycation in these proteins, and is the concentration of plasma glucose over the lifetime of the protein. This useful test has been utilized in previous clinical studies of natural products3 4 and is an adjunct to the A1C and other fasting glycemic measurements, and reflects intermediate-term (previous 2-3 weeks) glycemic change. One mL of serum or plasma will be collected, followed by centrifuge separation within 45 minutes of collection, and analyzed using standard colorimetric assay methodology (LabCorp, Inc.).	Baseline and study end (12 weeks from baseline)
Primary	GlycoMark	A blood test commonly used in clinical practice to determine peak hyperglycemia. The GlycoMark test provides accurate recognition of recent glycemic deterioration or improvement (within the previous 2-4 weeks)5 6 and is commonly given adjacently to A1C (a longer-term indicator of glycemic change) in clinical practice. One mL of serum or plasma will be collected, followed by centrifuge separation within 60 minutes of collection, and analyzed using standard enzymatic colorimetric assay methodology (LabCorp, Inc.).	Baseline and study end (12 weeks from baseline)
Secondary	Lipid profile	A standard lipid panel consisting of total cholesterol, LDL, HDL, and triglycerides will be compared at baseline and the 12-week follow up visit. One mL of serum or plasma will be collected for all lipid parameters after 8 -12 hours of fasting and in the manner as described above, followed by centrifuge separation within 45 minutes of collection, and analyzed using standard enzymatic methodology (LabCorp, Inc.).	Baseline and study end (12 weeks from baseline)
Secondary	Inflammation	High-sensitivity C-reactive protein (Hs-CRP) is a common measure of inflammation that is commonly collected in clinical practice. Samples will undergo analysis by latex immunoturbidimetry on a COBAS Integra 800 (Roche, Germany).	Baseline and study end (12 weeks from baseline)
Secondary	Supplement compliance assessed using participant daily diary		Study end (12 weeks from baseline)
Secondary	Adverse events		Throughout the study and at study end (12 weeks from baseline)